Skip to main content
. 2022 Nov 22;17(11):e0276462. doi: 10.1371/journal.pone.0276462

Fig 1. Genetic engineering and characterization of 833c&Freso.

Fig 1

(A) Plasmid map for 833c&Freso heavy chain expression. Fresolimumab single-chain variable fragment (scFv) was cloned into the 3’ end of the 833c CH3 domain. (B) 833c&Freso schematic: scFv is attached to the CH3 domain at the 3’ end. Red: human domains, blue: murine domains. CR: constant region, VH and VL: variable regions. (C) Size exclusion chromatography and (D) Reducing SDS-PAGE of purified 833c&Freso. (E) ELISA binding to rat aminopeptidase P2 of 833c&Freso (triangles), 833cX&Freso (circles) and 833c (squares) (see Methods). (F) ELISA binding to TGF-β1 of 833c&Freso (triangle, black), 833cX&Freso (triangle, gray), fresolimumab (squares) and huIgG4, a isotype-matched control IgG for fresolimumab (open circles) (see Methods).